Department of Pharmacy Services, Mayo Clinic, Rochester, MN.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN.
Mayo Clin Proc. 2019 Aug;94(8):1567-1581. doi: 10.1016/j.mayocp.2018.12.011. Epub 2019 Jun 1.
Nontuberculous mycobacteria (NTM) comprise a heterogeneous group of organisms, with only a small subset known to cause disease in humans. Although NTM infection is not a reportable disease, both the increasing clinical recognition and recent advancements in laboratory diagnostic capabilities of NTM infections in immunocompromised and immunocompetent patients are rapidly evolving. We reviewed antimicrobial agents used to treat the most frequently encountered NTM infections and examined optimized drug dosing strategies, toxicity profiles, drug-drug interactions, and the role of therapeutic drug monitoring. Antimicrobial susceptibility testing and patient monitoring on therapy were also examined. We used PubMed to review the published literature on the management of select NTM pathogens, the common syndromes encountered since 2000, and select pharmacokinetic principles of select antimicrobial agents used since 1990. We included select clinical trials, systematic reviews, published guidelines, and observational studies when applicable. The prolonged duration and the necessity for combination therapy for most forms of NTM disease can be problematic for many patients. A multidisciplinary care team that includes pharmacy engagement may help increase rates of optimal patient tolerability and successful treatment completion.
非结核分枝杆菌(NTM)是一组异质性的生物体,只有一小部分已知会导致人类患病。尽管 NTM 感染不是一种报告性疾病,但在免疫功能低下和免疫功能正常的患者中,NTM 感染的临床认识不断提高,实验室诊断能力也在不断提高。我们回顾了用于治疗最常见 NTM 感染的抗菌药物,并研究了优化的药物剂量策略、毒性特征、药物相互作用以及治疗药物监测的作用。还检查了抗菌药物敏感性测试和治疗期间的患者监测。我们使用 PubMed 回顾了有关选择 NTM 病原体管理、2000 年以来常见综合征以及 1990 年以来选择抗菌药物的选择药代动力学原则的已发表文献。我们包括了一些临床试验、系统评价、已发布的指南和观察性研究(在适用的情况下)。大多数形式的 NTM 疾病的治疗时间长且需要联合治疗,这可能会给许多患者带来问题。包括药剂师参与的多学科护理团队可能有助于提高最佳患者耐受性和成功完成治疗的比率。